# A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

> **NCT04071262** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 6 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT04071262
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-20
- **Primary completion:** 2021-02-12
- **Final completion:** 2021-08-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04071262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04071262, "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04071262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*